SCHEMBL4066977

SCHEMBL4066977

NC(=O)c1cc(F)ccc1C[C@H](C[C@@H](O)[CH]Cc1ccccc1)C(N)=O

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 1/20 0.36
CYP2C19 P33261 1/20 0.36
PSMB5 P28074 3/20 0.36
EPHX1 P07099 1/20 0.34
PLA2G10 O15496 4/20 0.34
PLA2G2A P14555 4/20 0.34
FCER2 P06734 2/20 0.34
MMP3 P08254 1/20 0.34
MMP9 P14780 1/20 0.34
PLA2G1B P04054 1/20 0.33
PLA2G5 P39877 1/20 0.33
PLA2G2C Q5R387 1/20 0.33
PLA2G12B Q9BX93 1/20 0.33
PLA2G12A Q9BZM1 1/20 0.33
PLA2G2F Q9BZM2 1/20 0.33
PLA2G3 Q9NZ20 1/20 0.33
PLA2G2E Q9NZK7 1/20 0.33
PLA2G2D Q9UNK4 1/20 0.33
SLC1A1 P43005 2/20 0.33
MDM2 Q00987 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4063820 0.89 KDM4E (0.37) CYP2C19PLA2G10PLA2G2APLA2G1BPLA2G5
SCHEMBL4062969 0.87 ADRA1D (0.36) EPHX1PLA2G10PLA2G2ASLC1A1
SCHEMBL4060239 0.85 EPHX1 (0.40) EPHX1PLA2G10PLA2G2APLA2G5
SCHEMBL4070172 0.84 KMT2A (0.33) EPHX1PLA2G10PLA2G2APLA2G1BPLA2G5
SCHEMBL4061937 0.81 HMGB1 (0.34) CYP3A4CYP2C19EPHX1PLA2G10PLA2G2A
SCHEMBL4064865 0.80 TDP1 (0.38) PSMB5EPHX1SLC1A1
SCHEMBL4064377 0.80 ADRA1D (0.35) EPHX1PLA2G10PLA2G2APLA2G1BPLA2G5
SCHEMBL7681396 0.79 AKR1B1 (0.37) EPHX1SLC1A1
SCHEMBL4070496 0.78 HMGB1 (0.39) PLA2G10PLA2G2APLA2G1BPLA2G5PLA2G2C
SCHEMBL4070562 0.78 PLA2G10 (0.39) PLA2G10PLA2G2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0966443-B1 HETEROARYL-HEXANOIC ACID AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS SELECTIVE INHIBITORS OF MIP-1-ALPHA BINDING TO ITS CCR1 RECEPTOR PFIZER (US) 2009-01-28 EP disclosed
US-20020198207-A1 Novel Hexanoic acid derivatives KATH JOHN CHARLES (US) 2002-12-26 US disclosed
US-6403587-B1 AUTOIMMUNE DISEASES, ACUTE AND CHRONIC INFLAMMATORY CONDITIONS, ALLERGIC CONDITIONS, INFECTION ASSOCIATED WITH INFLAMMATION, VIRAL, TRANSPLANTATION TISSUE REJECTION, ATHEROSCLEROSIS, RESTENOSIS, HIV INFECTIVITY, AND PFIZER INC. 2002-06-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020198207-A1 Novel Hexanoic acid derivatives HCAR3, HCAR1, FFAR1 CYP3A4 1637/4885CYP2C19 3140/4885PSMB5 2701/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.